Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 10801186

Platelets.

J N George
View original source ↗Export metadata ↓

Abstract

Platelets, derived from megakaryocyte cytoplasm, have a critical role in normal haemostasis, and in thrombotic disorders. The development of megakaryocytes is controlled by thrombopoietin, which binds to c-mpl on the surface of platelets and megakaryocytes. Platelet membrane glycoproteins mediate binding to subendothelial tissue and aggregation into haemostatic plugs. Thrombocytopenia and disorders of platelet function cause petechiae and mucocutaneous bleeding. Drugs causing specific inhibition of platelet function are important in the treatment of cardiovascular and cerebrovascular disease.

Explore related subjects

Blood Platelet DisordersBlood PlateletsFemaleHumansPlatelet Glycoprotein GPIb-IX ComplexPlatelet Membrane GlycoproteinsPregnancyPregnancy Complications, HematologicReceptors, Cell SurfaceThrombopoietinJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J N George. 2000-04-29. Platelets.. https://doi.org/10.1016/s0140-6736(00)02175-9

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.

Familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML) is an autosomal dominant familial platelet disorder characterized by thrombocytopenia and a propensity to develop AML. Mutation analyses of RUNX1 in 3 families with FPD/AML showing linkage to chromosome 21q22.1 revealed 3 novel heterozygous point mutations (K83E, R135fsX177 (IVS4 + 3delA), and Y260X). Functional investigations of the 7 FPD/AML RUNX1 Runt domain point mutations described to date (2 frameshift, 2 nonsense, and 3 missense mutations) were performed. Consistent with the position of the mutations in the Runt domain at the RUNX1-DNA interface, DNA binding of all mutant RUNX1 proteins was absent or significantly decreased. In general, missense and nonsense RUNX1 proteins retained the ability to heterodimerize with PEBP2beta/CBFbeta and inhibited transactivation of a reporter gene by wild-type RUNX1. Colocalization of mutant RUNX1 and PEBP2beta/CBFbeta in the cytoplasm was observed. These results suggest that the sequestration of PEBP2beta/CBFbeta by mutant RUNX1 may cause the inhibitory effects. While haploinsufficiency of RUNX1 causes FPD/AML in some families (deletions and frameshifts), mutant RUNX1 proteins (missense and nonsense) may also inhibit wild-type RUNX1, possibly creating a higher propensity to develop leukemia. This is consistent with the hypothesis that a second mutation has to occur, either in RUNX1 or another gene, to cause leukemia among individuals harboring RUNX1 FPD/AML mutations and that the propensity to acquire these additional mutations is determined, at least partially, by the initial RUNX1 mutation.

Blood Platelet Disorders↗
PubMed2002

A variant of the Sebastian platelet syndrome with unique neutrophil inclusions.

The Sebastian platelet syndrome (SPS) is a hereditary giant platelet disorder characterized by thrombocytopenia and the presence of neutrophil inclusions identical to those present in neutrophils of patients with another giant platelet disorder, the Fechtner platelet syndrome (FPS). Patients with SPS differ from those with FPS in that they lack the clinical features of the Alport syndrome (high frequency hearing loss, congenital cataracts and chronic interstitial nephritis). The present study has evaluated six patients who resemble individuals with SPS, but have uniquely different neutrophil inclusions. Ultrastructural features of the neutrophil inclusions of the new variant are presented and compared with those found in other giant platelet disorders including classic SPS, FPS and the May-Hegglin anomaly, as well as the Chediak-Higashi syndrome.

Blood Platelet Disorders↗
PubMed2002

Human platelet Galphaq deficiency is associated with decreased Galphaq gene expression in platelets but not neutrophils.

G-proteins play an important role in platelet signal transduction and regulate responses upon activation of G-protein coupled receptors (GPCR). We have previously reported a patient with impaired platelet responses associated with deficiency in platelet Galphaq. To understand the molecular basis for this defect, the cDNA sequence encoding Galphaq (1080 bp) was obtained by reverse-transcription and polymerase chain reaction of platelet RNA; the cDNA sequence showed no mutations in the patient. Platelet Galphaq mRNA levels were decreased by >50% compared to normal subjects; platelet Galphai2 mRNA levels were normal. Neutrophil calcium mobilization and elastase secretion, upon activation with several agonists, and neutrophil Galphaq mRNA and protein levels were normal. These studies demonstrate that the patient has a defect in Galphaq gene expression in platelets but not neutrophils, possibly due to defects in transcriptional regulation or mRNA stability, and suggest a hematopoietic-lineage specific defect.

Blood Platelet Disorders↗